In clinical trials, conflicts of interest can arise when investigators have financial interests in the outcomes. They may own stock in the company developing the drug or receive consulting fees. These financial incentives can influence the way trials are designed, conducted, and reported, potentially compromising patient safety and the validity of the trial results.
